Unbranded Biologics: An Overview

Dr David Charles, MD, opens a discussion surrounding the increasing usage and unique characteristics of biologics.

Distinctions between unbranded biologics, branded biologics, and biosimilars are explored by David Charles, MD.

Dr Charles discusses the clinical impacts that nonmedical switching of biologic treatments can have on quality of patient care.

Dr Charles provides his closing insights, focusing on unbranded biologics targeted for pipeline development.

Kareem Karara, PharmD, BCPS, CCHP continues this discussion on unbranded biologics, discussing payer priorities for treatment options.

Dr Karara discusses evolution of the biologics space and highlights important regulatory definitions.

Differences between biologics – both branded and unbranded – and biosimilars are explored by Dr Karara.

Dr Karara provides insight into how unbranded biologics are impacting the overall treatment landscape.

Study-based findings provide support for considerable implications of multiple switching between biosimilar and originator products.

Kareem Karara discusses several factors impacting the affordability of biologics for patient care pathways.

With his closing thoughts, Kareem Karara looks to the potential pipeline biologic development of biosimilars and unbranded biologics.